TW202116752A - 吡唑衍生物之鹽及吡唑衍生物之製劑 - Google Patents

吡唑衍生物之鹽及吡唑衍生物之製劑 Download PDF

Info

Publication number
TW202116752A
TW202116752A TW109123069A TW109123069A TW202116752A TW 202116752 A TW202116752 A TW 202116752A TW 109123069 A TW109123069 A TW 109123069A TW 109123069 A TW109123069 A TW 109123069A TW 202116752 A TW202116752 A TW 202116752A
Authority
TW
Taiwan
Prior art keywords
salt
preparation
phenyl
group
alkyl
Prior art date
Application number
TW109123069A
Other languages
English (en)
Chinese (zh)
Inventor
杉本八郎
奥田充顕
中野眞人
髙見真子
Original Assignee
日商綠色科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商綠色科技股份有限公司 filed Critical 日商綠色科技股份有限公司
Publication of TW202116752A publication Critical patent/TW202116752A/zh

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109123069A 2019-07-08 2020-07-08 吡唑衍生物之鹽及吡唑衍生物之製劑 TW202116752A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-127252 2019-07-08
JP2019127252 2019-07-08

Publications (1)

Publication Number Publication Date
TW202116752A true TW202116752A (zh) 2021-05-01

Family

ID=74115288

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109123069A TW202116752A (zh) 2019-07-08 2020-07-08 吡唑衍生物之鹽及吡唑衍生物之製劑

Country Status (3)

Country Link
JP (1) JPWO2021006267A1 (https=)
TW (1) TW202116752A (https=)
WO (1) WO2021006267A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025254133A1 (ja) * 2024-06-05 2025-12-11 グリーン・テック株式会社 プリオン病の予防剤及び/又は治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141228A1 (ja) * 2011-04-11 2012-10-18 株式会社ファルマエイト 新規ピラゾール誘導体
WO2013059664A1 (en) * 2011-10-21 2013-04-25 Seachaid Pharmaceuticals, Inc. Pharmaceutical compositions and uses thereof
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
CN104903297A (zh) * 2012-10-10 2015-09-09 绿色科技株式会社 新型吡唑衍生物
CN105848644A (zh) * 2013-12-23 2016-08-10 埃斯特韦实验室有限公司 经口药物组合物
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
EP3266445B1 (en) * 2015-03-02 2022-05-11 Takeda Pharmaceutical Company Limited Suspension or composition containing nano-cocrystal and manufacturing method therefor

Also Published As

Publication number Publication date
JPWO2021006267A1 (https=) 2021-01-14
WO2021006267A1 (ja) 2021-01-14

Similar Documents

Publication Publication Date Title
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
KR20170132881A (ko) Parp 억제제 고체약물제형 및 그 용도
US10688110B2 (en) Complexes of Celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
DE202008018063U1 (de) Pharmazeutischer Hilfsstoffkomplex
US10383872B2 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
CN101516870B (zh) 苯并咪唑基吡啶基醚的盐以及其制剂
US9566268B2 (en) Solid dispersions of insoluble drug and preparation method thereof
Lee et al. Montelukast microsuspension with hypromellose for improved stability and oral absorption
TW202116752A (zh) 吡唑衍生物之鹽及吡唑衍生物之製劑
WO2019016673A2 (en) STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
EP3250188B1 (en) Pharmaceutical composition comprising aprepitant and method for the preparation thereof
CN110035756A (zh) 含有他达拉非的药物配制品
KR101956586B1 (ko) 약제학적 조성물 및 이의 제조방법